MX2009011922A - Tetrahidrobenzazepinas ariloxi- y heteroariloxi-sustituidas y uso de las mismas para bloquear reabsorcion de norepinefrina, dopamina y serotonina. - Google Patents

Tetrahidrobenzazepinas ariloxi- y heteroariloxi-sustituidas y uso de las mismas para bloquear reabsorcion de norepinefrina, dopamina y serotonina.

Info

Publication number
MX2009011922A
MX2009011922A MX2009011922A MX2009011922A MX2009011922A MX 2009011922 A MX2009011922 A MX 2009011922A MX 2009011922 A MX2009011922 A MX 2009011922A MX 2009011922 A MX2009011922 A MX 2009011922A MX 2009011922 A MX2009011922 A MX 2009011922A
Authority
MX
Mexico
Prior art keywords
heteroaryloxy
aryloxy
norepinephrine
serotonin
dopamine
Prior art date
Application number
MX2009011922A
Other languages
English (en)
Inventor
Richard E Olson
Bruce F Molino
Shuang Liu
Aruna Sambandam
Yuh-Lin Allen Yang
Original Assignee
Amr Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amr Technology Inc filed Critical Amr Technology Inc
Publication of MX2009011922A publication Critical patent/MX2009011922A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen en la presente invención compuestos derivados de tetrahidrobenzazepina ariloxi- y heteroariloxisustituidos representados por las fórmulas (I) (A-E) que tienen la siguiente estructura: (ver fórmula (I) (A-E)) en donde el átomo de carbono designado * está en la configuración R o 5 y los sustituyentes X y R1-R9 son como se define en la presente.
MX2009011922A 2007-05-10 2008-05-08 Tetrahidrobenzazepinas ariloxi- y heteroariloxi-sustituidas y uso de las mismas para bloquear reabsorcion de norepinefrina, dopamina y serotonina. MX2009011922A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91720007P 2007-05-10 2007-05-10
PCT/US2008/063043 WO2008141082A1 (en) 2007-05-10 2008-05-08 Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

Publications (1)

Publication Number Publication Date
MX2009011922A true MX2009011922A (es) 2009-11-18

Family

ID=40002594

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011922A MX2009011922A (es) 2007-05-10 2008-05-08 Tetrahidrobenzazepinas ariloxi- y heteroariloxi-sustituidas y uso de las mismas para bloquear reabsorcion de norepinefrina, dopamina y serotonina.

Country Status (14)

Country Link
US (1) US8987252B2 (es)
EP (1) EP2146720A4 (es)
JP (1) JP5566282B2 (es)
KR (1) KR20100017767A (es)
CN (1) CN101686982A (es)
AU (1) AU2008251558B2 (es)
BR (1) BRPI0811200A8 (es)
CA (1) CA2685861A1 (es)
CO (1) CO6420345A2 (es)
EA (1) EA017308B1 (es)
IL (1) IL201923A0 (es)
MX (1) MX2009011922A (es)
NZ (1) NZ580802A (es)
WO (1) WO2008141082A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778639B1 (en) 2004-07-15 2015-09-02 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
MX2011011901A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
KR101830447B1 (ko) * 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
WO2012024397A2 (en) 2010-08-17 2012-02-23 Albany Molecular Research, Inc. 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
CN103664974B (zh) * 2012-09-17 2016-12-21 中国科学院上海药物研究所 芳基[a]吲哚[2,3-g]并喹嗪类化合物、其制备方法、药物组合物及其应用
PL2940008T3 (pl) * 2012-12-26 2017-10-31 Sanwa Kagaku Kenkyusho Co Nowa pochodna benzoazepiny i jej zastosowanie farmaceutyczne
WO2015161016A1 (en) * 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Bicyclic cgrp receptor antagonists
CN112209844A (zh) * 2020-10-22 2021-01-12 上海吉奉生物科技有限公司 一种3-甲氨基丙酸的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988690A (en) 1982-06-14 1991-01-29 Hoechst-Roussel Pharmaceuticals Inc. 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof
JPS6394239A (ja) 1986-10-08 1988-04-25 Konica Corp 色素画像の安定性を改良したハロゲン化銀写真感光材料
YU155791A (sh) 1990-09-25 1994-01-20 Agouron Pharmaceuticals Inc. Antiproliferativna supstituisana triciklična jedinjenja
US5202319A (en) 1991-09-23 1993-04-13 Hoechst-Roussel Pharmaceuticals Inc. Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines
US5416118A (en) * 1992-04-09 1995-05-16 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme A: cholesterol acyl transferase
TW527355B (en) * 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US6576664B1 (en) * 1997-08-18 2003-06-10 Bristol-Myers Squibb Pharma Company Inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
US6955873B1 (en) * 2000-08-04 2005-10-18 Kenneth Blum Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors
DE10028575A1 (de) * 2000-06-14 2002-03-14 Basf Ag Integrinliganden
US6809092B2 (en) * 2000-01-26 2004-10-26 Ono Pharmaceutical Co., Ltd. Benezene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient
WO2003068753A1 (fr) * 2002-02-14 2003-08-21 Ono Pharmaceutical Co., Ltd. Composes a noyau fusionne contenant n-carbamoyle azote et medicaments contenant ces composes comme ingredients actifs
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
CA2529227A1 (en) * 2003-06-26 2005-01-06 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
JPWO2005040135A1 (ja) * 2003-10-24 2007-03-08 小野薬品工業株式会社 抗ストレス薬およびその医薬用途
AU2005221678B2 (en) * 2004-03-09 2008-10-09 National Health Research Institutes Pyrrolidine compounds
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
KR20080044840A (ko) * 2005-07-15 2008-05-21 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도
JP2011116663A (ja) 2008-05-30 2011-06-16 Otsuka Pharmaceut Co Ltd ベンゾジアゼピン化合物

Also Published As

Publication number Publication date
JP5566282B2 (ja) 2014-08-06
EP2146720A4 (en) 2012-01-18
AU2008251558B2 (en) 2012-12-20
CA2685861A1 (en) 2008-11-20
EP2146720A1 (en) 2010-01-27
BRPI0811200A2 (pt) 2014-10-29
KR20100017767A (ko) 2010-02-16
JP2010527334A (ja) 2010-08-12
US20100210624A1 (en) 2010-08-19
US8987252B2 (en) 2015-03-24
AU2008251558A1 (en) 2008-11-20
IL201923A0 (en) 2010-06-16
WO2008141082A1 (en) 2008-11-20
CN101686982A (zh) 2010-03-31
EA017308B1 (ru) 2012-11-30
EA200971045A1 (ru) 2010-06-30
NZ580802A (en) 2012-09-28
CO6420345A2 (es) 2012-04-16
BRPI0811200A8 (pt) 2015-09-22

Similar Documents

Publication Publication Date Title
PH12014501033A1 (en) Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
MX2009011922A (es) Tetrahidrobenzazepinas ariloxi- y heteroariloxi-sustituidas y uso de las mismas para bloquear reabsorcion de norepinefrina, dopamina y serotonina.
EA017249B8 (ru) Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
ME00681B (me) Jedinjenje indola
MX2009013276A (es) Compuestos anti-inflamatorios de ciclobutenodiona sustituida.
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
TN2011000053A1 (en) Organic compounds
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
UA105185C2 (uk) Піроли
MX2010001576A (es) Compuestos 3´sustituidos que tienen afinidad con el receptor 5-hidroxitriptamina 6 (5-ht6).
IL204936A0 (en) Preparation of dihydropyrrol derivatives as intermediates
UA96015C2 (en) Therapeutic agents
WO2012024397A3 (en) 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
DE602006009789D1 (de) Acetylenderivate
EA201100920A1 (ru) Новые гербициды
MY157497A (en) Pyrazinooxazepine derivatives
MX2009008324A (es) Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6.
MX2009008028A (es) Agentes antiparasitarios.
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
IL185545A0 (en) Method of preparation of pure 4-pyrrolidinophenylbenzyl ether derivatives as maob inhibitors
EA201101097A1 (ru) Новые микробиоциды
EA201170100A1 (ru) Алканолпиперазиновые производные бензотиофена и их применение в качестве антидепрессанта
TW200631952A (en) Benzdioxan piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
DE602008002598D1 (en) Cyclohexylderivate

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration